Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients

Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients

Abstract RIPK1 is a master regulator of inflammatory signaling and cell death and increased RIPK1 activity is observed in human diseases, including Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). RIPK1 inhibition has been shown to protect against cell death in a range of preclinica...

Full description

Bibliographic Details
Main Authors: Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld, Jerome Oude Nijhuis, Peter Paul De Deyn, Salah Hadi, Jeffrey Harris, Richard M. Tsai, Andres Cruz‐Herranz, Fen Huang, Vincent Tong, Rebecca Erickson, Yuda Zhu, Kimberly Scearce‐Levie, Jennifer Hsiao‐Nakamoto, Xinyan Tang, Megan Chang, Brian M. Fox, Anthony A. Estrada, Robert J. Pomponio, Miguel Alonso‐Alonso, Moshe Zilberstein, Nazem Atassi, Matthew D. Troyer, Carole Ho
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13317

Internet

https://doi.org/10.1111/cts.13317

Similar Items